Puma biotechnology press release sale
Puma biotechnology press release sale
Puma biotechnology press release sale
Puma biotechnology press release sale
Puma biotechnology press release sale
Puma biotechnology press release sale

Puma biotechnology press release sale

Puma biotechnology press release sale, Securities class action filed against Puma Biotechnology Inc. after disappointing trial sale

$54.99

SKU: 7521141

Colour
  • Puma Biotechnology Inc. Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 HER2 Mutant HER2 Non Amplified Metastatic Breast Cancer at the 2019 San Antonio Breast...
  • Puma Biotechnology Inc CEO Alan Auerbach Sells 41 396 Shares
  • Puma Biotech starts phase II trial for lung cancer therapy By Investing
  • Puma biotechnology press hot sale release
Out of stock
Personalised:
: ( x )
Personalisation:
Edit
Remove Personalisation
Frasers Plus

Buy now.

Pay later.

Earn rewards

Representative APR: 29.9% (variable)

Credit subject to status. Terms apply.

Missed payments may affect your credit score

FrasersPlus